Trial Outcomes & Findings for Dose Response of a Tubule Occlusion Agent (NCT NCT01075256)

NCT ID: NCT01075256

Last Updated: 2013-06-03

Results Overview

Response to a constant jet of air applied to a hypersensitive tooth was evaluated using a 100 millimeter (mm) VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

195 participants

Primary outcome timeframe

Baseline to Day 15

Results posted on

2013-06-03

Participant Flow

Participants were recruited at the clinical site.

During the first 4 weeks of the study all participants brushed with an acclimatization toothpaste (sodium fluoride \[NaF\] toothpaste containing 1100 parts per million \[ppm\] fluoride \[F\]) for maintaining wash-out period and standardizing the oral conditions.

Participant milestones

Participant milestones
Measure
7.5% Sodium Calcium Phosphosilicate Toothpaste
Participants brushed their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
5% Sodium Calcium Phosphosilicate Toothpaste
Participants brushed their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
Placebo Toothpaste
Participants brushed their teeth for two minutes, twice daily for 15 days with a sodium calcium phosphosilicate free placebo toothpaste. All study treatments were fluoride free.
Overall Study
STARTED
64
66
65
Overall Study
COMPLETED
63
66
65
Overall Study
NOT COMPLETED
1
0
0

Reasons for withdrawal

Reasons for withdrawal
Measure
7.5% Sodium Calcium Phosphosilicate Toothpaste
Participants brushed their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
5% Sodium Calcium Phosphosilicate Toothpaste
Participants brushed their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
Placebo Toothpaste
Participants brushed their teeth for two minutes, twice daily for 15 days with a sodium calcium phosphosilicate free placebo toothpaste. All study treatments were fluoride free.
Overall Study
Withdrawal by Subject
1
0
0

Baseline Characteristics

Dose Response of a Tubule Occlusion Agent

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
5% Sodium Calcium Phosphosilicate Toothpaste
n=66 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
7.5% Sodium Calcium Phosphosilicate Toothpaste
n=63 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
Placebo Toothpaste
n=66 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with a sodium calcium phosphosilicate free placebo toothpaste. All study treatments were fluoride free.
Total
n=195 Participants
Total of all reporting groups
Age Continuous
38.30 years
STANDARD_DEVIATION 8.925 • n=99 Participants
37.63 years
STANDARD_DEVIATION 8.920 • n=107 Participants
36.61 years
STANDARD_DEVIATION 9.885 • n=206 Participants
37.51 years
STANDARD_DEVIATION 9.239 • n=7 Participants
Sex: Female, Male
Female
51 Participants
n=99 Participants
49 Participants
n=107 Participants
54 Participants
n=206 Participants
154 Participants
n=7 Participants
Sex: Female, Male
Male
15 Participants
n=99 Participants
14 Participants
n=107 Participants
12 Participants
n=206 Participants
41 Participants
n=7 Participants

PRIMARY outcome

Timeframe: Baseline to Day 15

Population: Intention to treat (ITT) population: All randomized participants who received at least one dose of investigational product who have at least one post-baseline efficacy measure. Missing data was not imputed. Due to drop outs, there was difference in number of participants analyzed.

Response to a constant jet of air applied to a hypersensitive tooth was evaluated using a 100 millimeter (mm) VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment.

Outcome measures

Outcome measures
Measure
7.5% Sodium Calcium Phosphosilicate Toothpaste
n=63 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
5% Sodium Calcium Phosphosilicate Toothpaste
n=66 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
Placebo Toothpaste
n=65 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with a sodium calcium phosphosilicate free placebo toothpaste. All study treatments were fluoride free.
Adjusted Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Visual Analog Scale (VAS) at Day 15
-26.1 Units on a scale
Interval -29.4 to -22.72
-28.4 Units on a scale
Interval -31.6 to -25.12
-26.2 Units on a scale
Interval -29.54 to -22.95

PRIMARY outcome

Timeframe: Baseline to Day 15

Population: ITT population: All randomized participants who received at least one dose of investigational product who have at least one post-baseline efficacy measure. Missing data was not imputed. Due to drop outs, there was difference in number of participants analyzed.

Response of exposed dentine surface to application of 1 ml freshly melted ice cold water was evaluated using a 100 mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment.

Outcome measures

Outcome measures
Measure
7.5% Sodium Calcium Phosphosilicate Toothpaste
n=63 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
5% Sodium Calcium Phosphosilicate Toothpaste
n=66 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
Placebo Toothpaste
n=65 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with a sodium calcium phosphosilicate free placebo toothpaste. All study treatments were fluoride free.
Adjusted Mean Change From Baseline in Cold Water Sensitivity Pain Response on a VAS at Day 15
-32.8 Units on a scale
Interval -37.55 to -28.0
-32.2 Units on a scale
Interval -36.86 to -27.59
-32.3 Units on a scale
Interval -37.04 to -27.6

SECONDARY outcome

Timeframe: Baseline to Day 7

Population: ITT population: All randomized participants who received at least one dose of investigational product who have at least one post-baseline efficacy measure. Missing data was not imputed. Due to drop outs, there was difference in number of participants analyzed.

Response to a constant jet of air applied to a hypersensitive tooth was evaluated using a 100 millimeter (mm) VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment.

Outcome measures

Outcome measures
Measure
7.5% Sodium Calcium Phosphosilicate Toothpaste
n=63 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
5% Sodium Calcium Phosphosilicate Toothpaste
n=66 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
Placebo Toothpaste
n=65 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with a sodium calcium phosphosilicate free placebo toothpaste. All study treatments were fluoride free.
Adjusted Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a VAS at Day 7
-16.4 Units on a scale
Interval -19.8 to -12.93
-17.4 Units on a scale
Interval -20.75 to -14.1
-16.4 Units on a scale
Interval -19.78 to -13.02

SECONDARY outcome

Timeframe: Baseline to Day 7

Population: ITT population: All randomized participants who received at least one dose of investigational product who have at least one post-baseline efficacy measure. Missing data was not imputed. Due to drop outs, there was difference in number of participants analyzed.

Response of exposed dentine surface to application of 1 ml freshly melted ice cold water was evaluated using a 100 mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment.

Outcome measures

Outcome measures
Measure
7.5% Sodium Calcium Phosphosilicate Toothpaste
n=63 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
5% Sodium Calcium Phosphosilicate Toothpaste
n=66 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
Placebo Toothpaste
n=65 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with a sodium calcium phosphosilicate free placebo toothpaste. All study treatments were fluoride free.
Adjusted Mean Change From Baseline in Cold Water Sensitivity Pain Response on a VAS at Day 7
-21.5 Units on a scale
Interval -26.14 to -16.81
-22.5 Units on a scale
Interval -26.99 to -17.93
-21.8 Units on a scale
Interval -26.44 to -17.21

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline to Day 10

Population: ITT population subset: A subset of randomized participants who received at least one dose of investigational product who have at least one post-baseline efficacy measure. Missing data was not imputed. Due to drop outs, there was difference in number of participants analyzed.

Response to a constant jet of air applied to a hypersensitive tooth was evaluated using a 100mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment.

Outcome measures

Outcome measures
Measure
7.5% Sodium Calcium Phosphosilicate Toothpaste
n=18 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
5% Sodium Calcium Phosphosilicate Toothpaste
n=18 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
Placebo Toothpaste
n=17 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with a sodium calcium phosphosilicate free placebo toothpaste. All study treatments were fluoride free.
Adjusted Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a VAS at Day 10
-28.7 Units on a scale
Interval -34.9 to -22.43
-22.7 Units on a scale
Interval -33.7 to -21.67
-28.2 Units on a scale
Interval -34.46 to -21.88

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline to Day 10

Population: ITT population subset: A subset of randomized participants who received at least one dose of investigational product who have at least one post-baseline efficacy measure. Missing data was not imputed. Due to drop outs, there was difference in number of participants analyzed.

Response of exposed dentine surface to application of 1 ml freshly melted ice cold water was evaluated using a 100 mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment.

Outcome measures

Outcome measures
Measure
7.5% Sodium Calcium Phosphosilicate Toothpaste
n=18 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
5% Sodium Calcium Phosphosilicate Toothpaste
n=18 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
Placebo Toothpaste
n=17 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with a sodium calcium phosphosilicate free placebo toothpaste. All study treatments were fluoride free.
Adjusted Mean Change From Baseline in Cold Water Sensitivity Pain Response on a VAS at Day 10
-34.7 Units on a scale
Interval -44.24 to -25.09
-31.3 Units on a scale
Interval -40.03 to -22.62
-34.7 Units on a scale
Interval -44.22 to -25.21

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline to Day 3

Population: ITT population subset: A subset of randomized participants who received at least one dose of investigational product who have at least one post-baseline efficacy measure. Missing data was not imputed. Due to drop outs, there was difference in number of participants analyzed.

Response to a constant jet of air applied to a hypersensitive tooth was evaluated using a 100 mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment.

Outcome measures

Outcome measures
Measure
7.5% Sodium Calcium Phosphosilicate Toothpaste
n=18 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
5% Sodium Calcium Phosphosilicate Toothpaste
n=18 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
Placebo Toothpaste
n=17 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with a sodium calcium phosphosilicate free placebo toothpaste. All study treatments were fluoride free.
Adjusted Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a VAS at Day 3
-13.5 Units on a scale
Interval -20.08 to -6.87
-12.3 Units on a scale
Interval -18.66 to -5.9
-11.1 Units on a scale
Interval -17.74 to -4.4

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline to Day 3

Population: ITT population subset: A subset of randomized participants who received at least one dose of investigational product who have at least one post-baseline efficacy measure. Missing data was not imputed. Due to drop outs, there was difference in number of participants analyzed.

Response of exposed dentine surface to application of 1 ml freshly melted ice cold water was evaluated using a 100 mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment.

Outcome measures

Outcome measures
Measure
7.5% Sodium Calcium Phosphosilicate Toothpaste
n=18 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
5% Sodium Calcium Phosphosilicate Toothpaste
n=18 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
Placebo Toothpaste
n=17 Participants
Participants brushed their teeth for two minutes, twice daily for 15 days with a sodium calcium phosphosilicate free placebo toothpaste. All study treatments were fluoride free.
Adjusted Mean Change From Baseline in Cold Water Sensitivity Pain Response on a VAS at Day 3
-19.3 Units on a scale
Interval -27.56 to -11.02
-16.9 Units on a scale
Interval -24.44 to -9.44
-17.6 Units on a scale
Interval -25.79 to -9.4

Adverse Events

7.5% Sodium Calcium Phosphosilicate Toothpaste

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

5% Sodium Calcium Phosphosilicate Toothpaste

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Placebo Toothpaste

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
7.5% Sodium Calcium Phosphosilicate Toothpaste
n=63 participants at risk
Participants brushed their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
5% Sodium Calcium Phosphosilicate Toothpaste
n=66 participants at risk
Participants brushed their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste. All study treatments were fluoride free.
Placebo Toothpaste
n=66 participants at risk
Participants brushed their teeth for two minutes, twice daily for 15 days with a sodium calcium phosphosilicate free placebo toothpaste. All study treatments were fluoride free.
Injury, poisoning and procedural complications
Injury
0.00%
0/63 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
3.0%
2/66 • Number of events 2 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
Injury, poisoning and procedural complications
Gingival Injury
1.6%
1/63 • Number of events 1 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
Injury, poisoning and procedural complications
Mouth Injury
0.00%
0/63 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
1.5%
1/66 • Number of events 1 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
Injury, poisoning and procedural complications
Thermal Burn
0.00%
0/63 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
1.5%
1/66 • Number of events 1 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
Infections and infestations
Pharyngitis Streptococcal
1.6%
1/63 • Number of events 1 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
Infections and infestations
Sinusitis
0.00%
0/63 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
1.5%
1/66 • Number of events 1 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
Infections and infestations
Tonsilitis
1.6%
1/63 • Number of events 1 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
Nervous system disorders
Sinus Headache
1.6%
1/63 • Number of events 3 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
Gastrointestinal disorders
Sensitivity of teeth
0.00%
0/63 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/66 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
1.5%
1/66 • Number of events 2 • All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place